Myelodysplastic Syndrome
Advertisement
Researchers developed and piloted a novel phone-delivered positive psychology intervention called PATH.
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Survival rates for myelodysplastic syndromes (MDS) varies widely – from months to decades – highlighting the need for ...
For post-transplant disease control in patients with myelodysplastic syndromes (MDS), donor lymphocyte infusion (DLI) has ...
Compared with placebo, treatment with CC-486, the oral formulation of the hypomethylating agent (HMA) azacitidine ...
Results from a randomized, proof-of-concept, phase II study demonstrated promising overall survival (OS), event-free survival ...
In a prospective multicenter study, older patients with myelodysplastic syndromes (MDS) who underwent reduced-intensity ...
Treatment with enasidenib, a small molecule inhibitor of mutant IDH2, showed promising clinical activity in patients with ...
A study published in Hematology, Transfusion & Cell Therapy found that FLT3, NPM1, IDH1, and IDH2 gene mutations may ...
A study published in Cancer Causes & Control observed that smoking, history of autoimmune disease, and benzene exposure ...
The use of poly (ADP-ribose) polymerase (PARP) inhibitors increased the risk of developing myelodysplastic syndromes (MDS) ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.